- Home
- SATX vs ACIU Comparison
SATX vs ACIU Comparison
Compare SATX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATX
- ACIU
- Stock Information
- Founded
- SATX 2012
- ACIU 2003
- Country
- SATX Israel
- ACIU Switzerland
- Employees
- SATX N/A
- ACIU N/A
- Industry
- SATX Radio And Television Broadcasting And Communications Equipment
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- SATX Technology
- ACIU Health Care
- Exchange
- SATX Nasdaq
- ACIU Nasdaq
- Market Cap
- SATX 177.6M
- ACIU 173.7M
- IPO Year
- SATX N/A
- ACIU 2016
- Fundamental
- Price
- SATX $2.05
- ACIU $1.68
- Analyst Decision
- SATX Strong Buy
- ACIU Strong Buy
- Analyst Count
- SATX 2
- ACIU 2
- Target Price
- SATX $2.25
- ACIU $10.00
- AVG Volume (30 Days)
- SATX 378.2K
- ACIU 133.4K
- Earning Date
- SATX 05-22-2025
- ACIU 04-30-2025
- Dividend Yield
- SATX N/A
- ACIU N/A
- EPS Growth
- SATX N/A
- ACIU N/A
- EPS
- SATX N/A
- ACIU N/A
- Revenue
- SATX $20,648,000.00
- ACIU $32,014,254.00
- Revenue This Year
- SATX $50.67
- ACIU N/A
- Revenue Next Year
- SATX $1.64
- ACIU $676.94
- P/E Ratio
- SATX N/A
- ACIU N/A
- Revenue Growth
- SATX 92.43
- ACIU 91.20
- 52 Week Low
- SATX $0.53
- ACIU $1.43
- 52 Week High
- SATX $2.39
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- SATX 66.42
- ACIU 46.75
- Support Level
- SATX $1.99
- ACIU $1.55
- Resistance Level
- SATX $2.02
- ACIU $1.79
- Average True Range (ATR)
- SATX 0.03
- ACIU 0.10
- MACD
- SATX -0.02
- ACIU 0.03
- Stochastic Oscillator
- SATX 100.00
- ACIU 66.67
About SATX SatixFy Communications Ltd.
SatixFy Communications Ltd is engaged in developing end-to-end next-generation satellite communication systems. This includes satellite payloads, user terminals, and modems, which are built on powerful in-house designed chipsets. Their products feature modems equipped with Software Defined Radio and Fully Electronically Steered Multi Beam Antennas that support the entire DVB-RCS2 / DVB-S2X industry standards as well as a complete SDR for any other waveform. The company has a geographical presence in the U.S. & Canada, the UK, and Other countries, with the majority of its revenue generated from the U.S. and Canada.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.